- Home
- ROIV vs CRL Comparison
ROIV vs CRL Comparison
Compare ROIV & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CRL
- Stock Information
- Founded
- ROIV 2014
- CRL 1947
- Country
- ROIV United Kingdom
- CRL United States
- Employees
- ROIV N/A
- CRL N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CRL Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ROIV Health Care
- CRL Health Care
- Exchange
- ROIV Nasdaq
- CRL Nasdaq
- Market Cap
- ROIV 7.8B
- CRL 7.1B
- IPO Year
- ROIV N/A
- CRL 2000
- Fundamental
- Price
- ROIV $10.99
- CRL $157.12
- Analyst Decision
- ROIV Buy
- CRL Hold
- Analyst Count
- ROIV 4
- CRL 14
- Target Price
- ROIV $17.50
- CRL $186.38
- AVG Volume (30 Days)
- ROIV 7.2M
- CRL 859.6K
- Earning Date
- ROIV 08-07-2025
- CRL 08-06-2025
- Dividend Yield
- ROIV N/A
- CRL N/A
- EPS Growth
- ROIV N/A
- CRL N/A
- EPS
- ROIV N/A
- CRL N/A
- Revenue
- ROIV $29,053,000.00
- CRL $4,022,597,000.00
- Revenue This Year
- ROIV $2.64
- CRL N/A
- Revenue Next Year
- ROIV $378.09
- CRL $2.49
- P/E Ratio
- ROIV N/A
- CRL N/A
- Revenue Growth
- ROIV N/A
- CRL N/A
- 52 Week Low
- ROIV $8.73
- CRL $91.86
- 52 Week High
- ROIV $13.06
- CRL $254.15
- Technical
- Relative Strength Index (RSI)
- ROIV 44.89
- CRL 67.60
- Support Level
- ROIV $10.83
- CRL $148.41
- Resistance Level
- ROIV $11.82
- CRL $160.40
- Average True Range (ATR)
- ROIV 0.32
- CRL 4.71
- MACD
- ROIV -0.07
- CRL 0.42
- Stochastic Oscillator
- ROIV 16.75
- CRL 81.08
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.